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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
 
 There are a number of therapies used for the treatment of Type I Diabetes 
Mellitus, but no cure. They can include daily insulin injections, organ transplantation, 
islet transplantation, and cellular encapsulation. Cellular encapsulation is a novel 
approach for the treatment of several pathologies, including diabetes. Capsules are 
fabricated using alginate, a crude product polysaccharide comprised of mannuronic and 
guluronic acid residues acquired from alga [1]. Many variables need to be controlled 
during the fabrication of these alginate-based capsules such as mechanical strength, pore 
size, and biocompatibility. Until now, biocompatibility measurements of the bioartifical 
pancreas have been made histologically, which allows for considerable biological 
variability and difficulty in constructing a timeline of immune response because only one 
data point can be obtained per animal. For this experiment, in vivo bioluminescence 
imaging using a Nuclear Factor-kappa Beta (NF-kB) marker allows unlimited 
measurements of biocompatibility to be made in real time. NF-kB is a transcription factor 
that plays a critical upstream role in coordinating the inflammatory and wound healing 
cascade. Acquiring information from the same mouse repeatedly to construct a time line 
of immune response allows each new data point an accurate reference to the last, instead 
of relying on data points acquired from different animals. This is in part made possible 
because each mouse can be used as its own control. The requirement for fewer animals 
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reduces the reliance on statistical analysis and increases the importance of real time data. 
Collected data can reveal important information about the immune response time course. 
 The ultimate goal of diabetic reversal is to mimic metabolic control of 
blood/glucose levels. In a non-diabetic patient, insulin-producing beta cells are able to 
monitor and respond to glucose fluctuations continuously. Daily insulin injection is the 
most common therapy for type I diabetes mellitus, but complications from the lack of 
continuous blood/glucose regulation can occur. Most diabetic patients inject nearly four 
times daily. Bolus insulin injections do not accurately reflect endogenous insulin release 
in non-diabetic patients. Deviations from this control can result in hyperglycemia, whose 
complications over time can involve vessel wall deterioration and is a source of more 
serious diabetic ailments such as cardiovascular and renal disease. Even the most 
responsible diabetic patient is susceptible to the limitations of insulin injection therapy.  
Ideally, organ and islet transplantations should be able to imitate metabolic 
control of blood/glucose regulation, and success has been made [2]. However, secondary 
immunosuppressive side effects such as mucosal ulcers, malaise, risks of infection, and 
tumors, still hamper long-term efficacy of the transplantation. Steroids can induce graft 
failure, and other immunosuppressive drugs can be toxic to the islet cells and induce 
peripheral insulin resistance [2-4]. Some relevant areas of research attempting to 
circumvent the foreign tissue rejection problem are donor bone marrow infusion for 
tolerance induction, and use of monoclonal anti-bodies to impede co-stimulatory 
pathways of immune rejection [3, 5]. 
Lack of donor sources is a major impedance to the success of organ and islet 
transplantation. Research has shown that an average of two pancreata worth of islets is 
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necessary for diabetic reversal, doubling the number of human resources necessary to 
treat just one [2-4]. Conversely, there are many islet sources for xenograft 
transplantations. Xenograft tolerance is more difficult to attain than the allograft tolerance 
whose success is still not completely resolved. Cellular encapsulation offers an approach 
to the transplantation of allo- or xeno-islet cells without rejection or autoimmune 
complications [6]. Islet cells are sequestered inside alginate-based capsules whose walls 
have pores, approximately 72 kilodaltons, large enough for nutrients and hormone to 
diffuse, but small enough so the host immune system cannot reject the foreign cells 
inside.  Cellular encapsulation offers a means of circumventing immunosuppression and 
allowing islets to continuously monitor and adjust blood/glucose levels. There is inherent 
lag in the regulation of blood/glucose levels, as signals from the blood must diffuse 
through the capsule semi-permeable membrane to interact with the islets, and resulting 
hormones must diffuse back into the surrounding system. The extent of this temporal 
distortion differs depending on the methods and materials used to construct the capsules, 
and attempts to make responses instantaneous are being made. Lim and Sun, the first to 
pioneer microencapsulation for the use as a bioartificial pancreas, show an insulin release 
time delay of approximately 7 minutes after glucose load in vitro [7]. Cellular 
encapsulation is a promising solution to both the immunosuppression and limited 
allograft donor source dilemma. 
 Many variables such as size, mechanical strength, and diffusivity need to be 
accurately controlled during the fabrication of these alginate-based capsules. In addition, 
especially for transplantation purposes, it is important to regulate biocompatibility. 
Particularly non-biocompatible capsules can elicit fibrosis on the capsule wall capable of 
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causing islet necrosis [8-10]. Even empty capsules, without sequestered islet cells inside, 
have been shown to elicit immune responses. Several experiments have been conducted 
to quantify this, all using similar techniques. Capsules are fabricated and then implanted 
into the peritoneal cavity of mice. They are allowed to incubate for specified periods of 
time and are then recovered via peritoneal lavage. Capsules are examined for integrity 
and for the number of immune response cells in the area or adhered to the capsule walls. 
Labs then create quantitative scales to score the biocompatibility of the capsules based on 
their observations [1, 8-14]. Appropriate for these procedures, biocompatibility can be 
defined as the number of cells or cell layers surrounding the retrieved capsules. There are 
several disadvantages to these methods. A time line of immune response is hard to 
determine unless many animals are used because only one data point can be obtained per 
animal. Using many mice introduces sources of variance in data owing to inherent 
biological variability between the animals.  
To circumvent these problems, we propose an alternate method of monitoring 
immune response. In vivo bioluminescence imaging allows measurements of immune 
response to be acquired in real time. Transgenic mice expressing luciferase under the 
control of the proximal 5’ human immunodeficiency virus long terminal repeat, a known 
NF-kB dependent promoter sequence, are used. NF-kB initiates the transcription of many 
cytokines, chemokines, adhesion molecules, and proinflammatory genes [15-18]. When 
NF-kB binds to its promoter sequence to initiate transcription of immune response 
proteins, luciferase is also produced. Luciferase, in conjunction with its substrate, 
luciferin, catalyzes a bioluminescent reaction detectable by a sensitive charge coupled 
device camera. The amount of light (photons/sec/cm2/sr) detected by the camera is 
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therefore indicative of NF-kB activity, which is highly involved in regulating the immune 
response in not only the murine animal model, but humans as well [16, 18-21]. 
 
 
Immune Response 
 Immune response to implant materials can be initiated a number of ways. One of 
the simplest interactions occurs when ions, fluids, or pieces of the implant material is 
absorbed by the surrounding tissue, a phenomenon known as leaching. Likewise, 
swelling can occur when implant materials absorb ions or fluids from surrounding tissue. 
Both of these phenomenons are a result of diffusion, and occur after capsule 
transplantation [22]. Specific to the procedures conducted in this experiment, the event 
that first triggers immune response is trauma due to surgery. Natural killer cells of the 
host immune system act not only to cleanse the body of implanted foreign molecules, but 
local dead cells and cell fragments as well, of which there are many around the site of 
surgery and implantation. 
There exist a number of specific and non-specific mechanisms the human body 
uses to defend against foreign pathogens. Non-specific mechanisms require various 
phagocytic white cells and natural killer cells. There are two specific immune responses 
the body can engage to defend against all pathogens; one is a humoral response and the 
other a cell-mediated response. The reactions differ primarily on the location of 
pathogens; a humoral response is in response to pathogens in body fluids and a cell-
mediated response is mounted against intracellular pathogens. Transplantation of a bio-
artificial pancreas elicits both non-specific defenses against the implant materials, and 
primarily a specific humoral immune response if the sequestered islet cells are exposed to 
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the biological environment. This exposure can happen one of two ways. Capsule wall 
deterioration can expose the islet cells, and flawed encapsulation techniques can allow 
islet cells to become trapped in the capsule wall instead of being completely sequestered 
inside. 
 The inflammatory cascade begins with rapid dilation of capillaries, which leads to 
an increase in blood flow volume.  There is also an increase in vascular wall 
permeability, which allows more fluid and cells to permeate into the surrounding tissue. 
These are precursory events that lead to mounting of the cellular invasion phase of the 
immune response.  
To foster the increase in endothelial cell permeability, endothelial cells become 
“sticky” by the increase in adhesion molecule expression, which is initiated by NF-kB 
dependent cytokines IL-1 and TNF-α. The first step, rolling, is the initiation of the 
expression of endothelial selectins, proteins expressed on endothelial cell surfaces that 
promote weak interactions with leukocytes in the blood. The expression of these proteins 
is in part regulated by the NF-kB transcription factor [23-25]. The result is a slowing of 
immune response cells in the blood around the site of inflammation. The second step is 
the expression of β2, and eventually β1-integrins on leukocyte surfaces that ultimately 
foster the migration of leukocytes across the basement membrane. The expression of 
integrin proteins on leukocytes is partly under NF-kB control, but the translocation of the 
monocytes across the endothelial wall is also dependant on specific NF-kB dependant 
cytokines and chemokines [26, 27]. 
Chemotaxins, or chemoattractants, are polypeptide ligands responsible for 
amassing leukocytes. Chemoattractant concentration gradients trigger the extravasation 
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of those cells from the blood. Chemokines attract neutrophils to inflammatory sites via 
gradient-dependent enhancement of integrin dependent adhesion. For example, NF-kB 
dependent chemokine IL-8 is secreted by activated endothelial cells and bound to surface 
glycoproteins in a gradient dependent manner. Neutrophils already involved in selectin 
rolling are stimulated by IL-8 to express β2-integrins. These integrins in turn bind to 
ICAM1 endothelial counter-receptors, which are expressed in a gradient dependant 
manner as well. ICAM1 receptor expression is triggered by proinflammatory NF-kB 
dependant cytokines such as IL-1 and TNF-α [27]. Immune response cells migrate along 
the ICAM1 gradient from the endothelium into inflamed tissue via a process known as 
haptotaxis. There also exist monocyte chemotaxins that are selectively chemotactic for 
mononuclear leukocytes such as monocytes, macrophages, and lymphocytes.    
These steps are necessary to mount the cellular invasion phase of the immune 
process. There are a number of phagocytic leukocytes and natural killer cells that defend 
the body non-specifically. Non-specificity implies that cells do not discriminate on the 
particular pathogen; they will digest any number of different pathogens regardless of their 
cell-surface markers. No antibodies specific for the particular antigen are produced. 
Leukocytes depend primarily on phagocytosis to eliminate the pathogen. This process 
requires engulfing and digestion of fragments using digestive enzymes called lyzozymes, 
which are stored in cytoplasmic granules. Neutrophils, the first cells to appear at the site 
of injury, compromise approximately 65% of white blood cells, under normal 
physiological conditions, and are attracted to sites of inflammation by chemotaxis [28]. 
Neutrophils and eosinophils, another phagocytic cell line associated with the first line of 
defense with neutrophils, both have short life spans, hours in blood and several days in 
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tissue. Extensive presence of these two cells in an area of trauma can be evidence of 
chronic inflammation [22]. Monocytes, compromising only 5% of white blood cells, 
circulate in the blood, and then migrate into tissues to enlarge and change into 
macrophages, cells intimately involved in the specific humoral immune response.  
The next cells to arrive at a site of injury are called monocytes when in the blood. 
Once in the tissue, they enlarge and become macrophages. There exist specific resident 
populations of monocytes in tissues such as liver and lung that are able to react more 
quickly to trauma [16, 29]. Their role is similar to neutrophils, relying on phagocytosis, 
but because of their increased size, they can digest larger particles. Macrophages are 
capable of many other functions in addition to digesting pathogens. For example, they 
can fuse to become large multi-nucleated cells called foreign body giant cells that can 
digest even larger pathogens than those ingested by single macrophages. Macrophages 
play not only an important role in non-specific defense against pathogens, but are 
responsible for critical steps of the specific humoral response as well.  
A humoral immune response is dependent on B cells, helper T cells, and 
macrophages. The process is initiated by the phagocytic response of a macrophage to a 
foreign pathogen. The macrophage engulfs the pathogen, which is then partially digested. 
These partially digested fragments are presented on the surface of the macrophage by 
class II Major Histocompatibility Complex proteins. MHC proteins are self-marker 
proteins used to identify self and non-self cells. Breakdowns in the processing of MHC 
proteins and the immune cells that interact with them can result in autoimmune 
deficiencies. Class I MHC molecules are found on most nucleated cells in the body. Class 
II MHC molecules are restricted for a few cell types intimately involved with the immune 
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system, such as macrophages and B cells [28]. Once the pathogen fragments on the Class 
II MHC proteins are presented on the macrophage cell surface, the cell becomes an 
antigen-presenting cell (APC). 
Unlike macrophages and other non-specific leukocytes, T helper cells bind 
specifically to certain pathogens’-receptor complexes. A T helper cell, whose receptors 
are specific for the antigenic determinant presented by Class II MHC proteins on the 
surface of the APC, will bind to that macrophage. Molecules on the T helper cell called 
CD4 aid this binding phenomenon [30-32]. CD4 molecules have an affinity for certain 
molecules on the Class II MHC. Binding of these two cells will activate the T helper cell 
to replicate, resulting T helper cells still specific for the pathogen ingested by the 
macrophage.  
In order to mount the humoral response, B cells must participate simultaneously 
with T helper cells and macrophages. As opposed to neutrophils and macrophages that 
rely on phagocytosis of any pathogen, B cells are stimulated by antigens specific to their 
cell surface receptors. Each antigen activates a very small fraction of B cells in the body. 
Once the B cell ingests the antigen, it is partially digested and portions of it are coupled 
to Class II MHC proteins and the complex migrates and expresses itself on the B cell 
surface. Cloned T helper cells specific to the antigen ingested by both the macrophage 
and B cell, binds to the MHC complex on the B cell surface. This binding activates the B 
cell to replicate into effector cells called plasma cells. These plasma cells create proteins 
called antibodies, all specific to the antigen. Memory cells are also produced that can 
mount a second immune response much more quickly the next time the host is exposed to 
the same antigen. 
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One mediator that regulates the activation of T helper cells by APCs, and B cells 
by T helper cells, is the secretion of various cytokines, such as NF-kB dependent IL-1. 
The NF-kB transcription factor is a crucial upstream regulator of a number of cytokines 
and chemokines intimately involved in the inflammatory process [16, 18, 20, 29, 33, 34]. 
 
NF-kB Transcription Factor 
 Nuclear Factor kappa-Beta is a transcription factor that regulates gene 
transcription of various pro-inflammatory cytokines and chemokines [16, 18-20, 29, 33, 
34]. In addition, it also enhances the transcription of other genes such as growth factors, 
immunoreceptors, and adhesion molecules. Abnormal continuous activation of NF-kB 
has been shown to facilitate tumor growth [33, 34], and is also intimately involved in cell 
proliferation and differentiation in certain tissue types, demonstrating its ubiquitous 
nature [21, 35-41]. Various inhibitory proteins and positive/negative feedback loops 
tightly control NF-kB activity. These methods of regulation are important because 
cytokines are generally not stored intracellularly, and require production starting with 
transcription in the nucleus. As a result, transcription factors play a major role in 
regulating the inflammatory cascade via cytokine gene regulation. Although NF-kB plays 
an important role in regulating inflammatory pathways, it is unknown whether it 
contributes to the differential production of NF-kB dependent cytokines or in the 
coordination of the production of the resulting proteins [16].  
The group of Rel transcription factors is responsible for the regulation of 
expression of many genes. They are especially involved in regulating those involved in 
inflammatory and immune responses [21]. The Rel proteins act in protein-protein 
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interactions, DNA binding, and nuclear localization [17]. Of the many Rel proteins, some 
include NF-kB1 (p50/p105), NF-kB2 (p52/p100), RelA (p65), c-Rel, and RelB, which in 
combination with p50 and RelA, can be found in numerous cell types forming several 
hetero/homodimers. RelA and p50 constitute most of the cellular subunits, and the 
RelA/p50 heterodimer is the most ubiquitous and powerful activator of NF-kB dependent 
genes. Rel proteins contain a conserved 300 amino-acid sequence. These dimers bind to 
DNA at its promoter, a ten or 11 base pair sequence, but only RelA contains a 
transactivation domain at the C-terminal end that activates transcription. The different 
variations of NF-kB can function identically to the classic RelA/p50 dimer, and therefore 
all forms that bind to the NF-kB binding sites are referred to as NF-kB [16]. 
 The inactive form of NF-kB is sequestered in the cytoplasm of the cell (most 
information about NF-kB is derived from immune response cells such as lymphocytes, 
monocytes, and macrophages). Activation occurs when inhibitory proteins are 
phosphorylated, allowing NF-kB localization signals to relocate the dimer to the nucleus. 
Phosphorylation can be stimulated by a number of factors including radiation, UV light, 
chemical agents, viral proteins, bacterial endotoxins, and several cytokines [16]. Not only 
does the Rel family include select proteins allowing for several hetero/homodimers of 
NF-kB, but there also exists several inhibitory proteins, known as the IkB family of 
proteins. They include IkB-α, IkB-ε, IkB-β, and Bcl-3. This inhibitory family contains 
what is known as an “ankyrin repeat”, a 33 amino acid motif, which gets its name from 
being abundant in the protein ankyrin [21]. NF-kB inactivity is maintained by binding to 
I-kB, and although various signals and cell signaling pathways can stimulate NF-kB, 
most activation results from serine phosphorylation of the I-kB kinase complex. All of 
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these various dimers and inhibitory proteins highlight the complexities involved in 
regulating NF-kB dependent gene regulation.  
 Positive and negative feedback loops help to regulate NF-kB activation both 
intracellularly and extracellularly. Positive extracellular feedback control can occur, for 
example, when TNF-α and IL-1β are produced. The production of these cytokines 
requires NF-kB activation, and in turn, these cytokines activate NF-kB, amplifying the 
signal. Both intracellular and extracellular negative feedback control can occur, too. The 
IkB-α and p105 genes, NF-kB inhibitory units, both have NF-kB responsive elements in 
their promoter sequences. Increased p105 production also means increased p50 
homodimer is formed, because p105 is the precursor of the p50 subunit of NF-kB (figure 
1).  
 
 12
 
Figure 1. Regulation of NF-kB RelA/p50 dimer after cell stimulation [16]. 
 
Since the p50 subunit does not bind the inhibitory protein IkB efficiently, nor does it 
contain transcription-activating domains, it can efficiently translocate to the nucleus and 
compete against other NF-kB dimers for NF-kB binding sites. Negative extracellular 
feedback loops also help to diminish NF-kB activation. Increased TNF- α and IL-1β can 
produce a counter regulatory cytokine, IL-10. It has been shown that IL-10 can inhibit 
endotoxin-induced NF-kB activation in monocytes [16]. Synthesis of some, but not all, of 
both the Rel family of proteins as well as its inhibitors are autoregulated, demonstrating 
the complexity of NF-kB regulation. 
A specific example of this complex inhibitory process has been demonstrated in 
primary mouse embryo fibroblasts (PMEF). To examine the role of IkB-α, wild-type 
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(+/+) for IkB-α, heterozygous (+/-), and homozygous null (-/-) fibroblasts were 
constructed. The null cells did not exhibit constitutive NF-kB activation, as expected, nor 
was there any increase in NF-kB dependent proteins such as c-Rel, p65, p50, and p105. 
Therefore, IkB-α does not play a singularly important role in sequestering NF-kB in the 
cytoplasm of PMEF cells, and other proteins in the inhibitory family are probably 
responsible. In addition, activation of NF-kB with TNF-α showed increased p65 levels in 
the wild-type and heterozygous cells, as expected, however, it is unclear which 
cytoplasmic inhibitor released the transcription factor as p105 and p100 (which can 
inhibit NF-kB migration) levels did not change, and IkB-β is known not to be responsive 
to TNF-α [21]. This demonstrates briefly the complexities of NF-kB attenuation and 
activation in the cytoplasm. 
 Studies have concluded that protein synthesis is required for termination of an 
NF-kB response. To determine IkB-α’s role in this synthesis, wild type and null PMEFs 
were used. Each was treated with TNF-α for approximately 30 minutes and then allowed 
to incubate for 30-60 minutes after withdraw. The wild-type cells returned to basal levels 
of nuclear p65 about 30 minutes after TNF-α withdraw. However, nuclear p65 levels 
remained elevated in the null cells, indicating that IkB-α plays a crucial role not in 
sequestering NF-kB in the cytoplasm, but rather in regulating nuclear levels of p65 after 
withdraw of an NF-kB activating stimulus [21].  
As previously mentioned, it is unknown how responsible the NF-kB motif is for 
initiating transcription of specific cytokines and chemokines or in helping in the overall 
coordination of their production. Different cytokines are produced depending on the 
original signal as well as the tissue type. NF-kB also interacts with several other 
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transactivators and repressors, as well as promoter-bound transcription factors. As is 
typical of other transcription factors, NF-kB can have interactions with glucocorticoids 
that usually inhibit a factor’s ability to bind to promoter sequences in the DNA. Different 
hetero/homodimers can bind to similar binding sites, but with different affinities [42]. 
These characteristics highlight the complex regulation of cytokine transcription by the 
NF-kB transcription factor.  
 
Luciferin-Luciferase Complex 
 Many organisms, such as fireflies, fish, fungi, and bacteria, are capable of 
emitting light. Each organism emits light for different reasons ranging from 
communication to mating rituals. The differences in color, ranging from violet (400nm) 
to red (620 nm), seem to be loosely associated with the habitat in which the organism 
resides. It has been shown that the enzyme is responsible for the differences in emitted 
wavelengths [43]. Techniques have been developed to harness this bioluminescence and 
use it as a biological marker. 
All categorized insect luciferases consist of one polypeptide chain ranging from 
542-552 amino acid residues. The number of charged amino acid residues is nearly 
identical, and the main difference is the number of cysteine and tryptophan residues. 
Various experiments have been performed to determine why shifts in wavelengths exist 
between nearly homogenous luciferase polypeptide chains across families of insects. For 
example, for fireflies of the family Luciola, there is an 80% homology for the entire 
sequence, and a 90% homology for the 250 amino acid residue cluster closest the C-
terminus end. However, maximum bioluminescence between the species ranges from 
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538nm to 622nm. Proposed explanations vary from two stereo conformations of the 
oxyluciferin complex, to the polarity of specific amino acid residues, to the general 
effects of the protein microenvironment. At a pH of approximately 7.0, oxyluciferin from 
fireflies will emit a yellow-green light ranging from 500-700nm, with a peak wavelength 
at 563nm [44, 45]. These values are both pH and temperature dependent. 
Firefly luciferase is an enzyme responsible for the bioluminescence reaction. It 
catalyzes the oxidation of luciferin in the presence of O2, ATP, and Mg2+.  The first 
reaction catalyzed by the luciferase is the transformation of luciferin to luciferyl 
adenylate, with a subsequent release of inorganic pyrophosphate. The luciferase-luciferyl 
adenylate complex then reacts quickly with the molecular oxygen to produce the keto-
form of oxyluciferin, CO2, and AMP. [15, 44-46] (figure 2).  
 
 
Figure 2. Schematic of bioluminescent reaction [46]. 
 
This keto-form of oxyluciferin is an oxyluciferin molecule in a singlet electronically 
excited state. Proton removal is quick to ensue, transforming the keto-form into the enol 
form, emitting one quantum of light in the process [44]. One property that makes this 
bioluminescent reaction unique, and effective for this experiment, is that it does not 
require excitation energy in the form of light, but rather is chemically driven. 
The resulting light is capable of penetrating several centimeters of tissue [15]. A 
charge-coupled device camera can detect the photons externally. The camera chip and 
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accompanying software are designed to count the emitted photons per time per area per 
conic angle. The photon flux, or bioluminescence, is dependent on the amount of 
luciferase complementary DNA that is transcribed, which is dependent on NF-kB 
activation. This sequence of events allows this imaging system to be a method of 
quantifying NF-kB activation, and consequently, immune response.  
 
NF-kB Transgenic Mouse 
 The transgenic mice used in this experiment are crossed with C57L/J mice. They 
are housed and bred at Vanderbilt University, Nashville, TN. The mice are engineered to 
possess the proximal 5’ human immunodeficiency virus long terminal repeat, which is a 
well-documented NF-kB responsive promoter. This promoter sequence, containing a 
TATA box, drives the expression of photinus luciferase complementary DNA [15, 45, 
47]. It has been shown in primary cell culture that the NF-kB transcription factor is 
necessary for the proximal HIV-LTR transcriptional activity [15]. Injection of the 
substrate luciferin is required for bioluminescence, and is injected intraperitonealy. An 
example of bioluminescent mice after luciferin injection is shown below (figure 3). 
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 Figure 3. Bioluminescent photograph NF-kB transgenic mice after luciferin injection, 
dorsal view. Photograph is an overlay of two images, a black and white photograph 
overlaid with bioluminescent image. Photon counts are acquired from the 
bioluminescence present at the base of the skull behind the ears, where the dorsal-cervical 
fat-pad is located. Blue colored region represents bioluminescence. Bioluminescence at 
dorsal-cervical fat pad is due to post-surgical inflammation to the implants. 
Bioluminescence of the nose, ears, paws, and tail is due to tissue specific basal NF-kB 
activity. 
 
 
 
These transgenic mice have been used to monitor the effects of dexamethasone 
treatments on NF-kB activity and lung inflammation [15]. They have also been used to 
investigate multi-organ inflammatory responses to hepatic cryoablation [45].   
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CHAPTER II 
 
 
 
BIOLUMINESCENT IMAGING OF AN NF-kB TRANSGENIC MOUSE MODEL  
 
FOR MONITORING IMMUNE RESPONSE TO A BIOARTIFICIAL PANCREAS  
 
REAL TIME AND IN VIVO: VALIDATION OF THE METHOD  
 
 
 
Abstract 
 
 
 
 Cell encapsulation is a novel therapeutic approach for the treatment of Type I 
Diabetes Mellitus that circumvents both the immunosuppression and limited allograft 
donor source dilemma. Current methods for scoring the biocompatibility of the alginate-
based capsules that sequester Islets of Langerhans include fabrication and implantation 
into the peritoneal cavity of mice, incubation for specified periods of time, retrieval via 
peritoneal lavage, and observation of the number of cells or cell layers surrounding the 
capsules. This method allows only one data point to be obtained per animal. In this 
experiment we propose to measure biocompatibility real time and in vivo This new 
method of monitoring immune response using bioluminescent technology and a Nuclear 
Factor-kappa Beta sensitive transgenic mouse model allows unlimited data points to be 
acquired per animal, reduces the number of animals required to obtain statistically 
significant immune response data over time, and in turn reduces error associated with 
animal variability. NF-kB is a transcription factor that plays a critical upstream role in the 
coordination of the inflammatory and would healing cascades by initiating the 
transcription of many cytokines, chemokines, adhesion molecules, and proinflammatory 
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genes. Five types of capsules were monitored over 6 six weeks after transplantation into 
the dorsal-cervical fat pad, a capsule group, a bead group, a non-coated capsule group, a 
sham surgery group, and a control group. The bead, capsule, and non-coated capsule 
transplant groups allow the effects of capsule size and capsule wall composition on NF-
kB activity to be monitored. This imaging modality was able to detect statistically 
significant differences in NF-kB activity between pre and post-operative data points per 
mouse. It was also able to discern with significance an unexpected increase in NF-kB 
activity due to capsule size instead of capsule wall composition over a six week time 
period.  
 
Introduction 
The ultimate goal of diabetic reversal is to mimic metabolic control of 
blood/glucose levels. In a non-diabetic patient, insulin-producing beta cells are able to 
monitor and respond to glucose fluctuations continuously. There are a number of 
therapies used for the treatment of Type I Diabetes Mellitus, but no cure. They can 
include daily insulin injections, organ transplantation, islet transplantation, and cellular 
encapsulation. Cellular encapsulation is a novel approach for the treatment of several 
pathologies, including diabetes.  
Daily insulin injection is the most common therapy for type I diabetes mellitus, 
but allows complications from the lack of continuous blood/glucose regulation to arise. 
Ideally, organ and islet transplantations should be able to imitate metabolic control of 
blood/glucose regulation, and success has been made [2]. However, secondary 
immunosuppressive side effects such as mucosal ulcers, malaise, risks of infection, and 
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tumors, still hamper long-term efficacy of the transplantation. Steroids can induce graft 
failure, and other immunosuppressive drugs can be toxic to the islet cells and induce 
peripheral insulin resistance [2-4]. 
Lack of donor sources is a major impediment to the success of organ and islet 
transplantation. Research has shown that an average of two pancreata worth of islets is 
necessary for diabetic reversal, doubling the number of human resources necessary to 
treat just one [2-4]. Cellular encapsulation offers an approach to the transplantation of 
allo- or xeno-islet cells without rejection or autoimmune complications [6]. Islet cells are 
sequestered inside alginate-based capsules whose walls have pores large enough for 
nutrients and hormone to diffuse, but small enough so the host immune system cannot 
reject the foreign cells inside.   
Capsules are fabricated using alginate, a crude product polysaccharide comprised 
of mannuronic and guluronic acid residues acquired from alga [1]. Many variables need 
to be controlled during the fabrication of these alginate-based capsules such as 
mechanical strength, pore size, and biocompatibility. Particularly non-biocompatible 
capsules can elicit fibrosis on the capsule wall capable of causing islet necrosis [8-10]. 
Even empty capsules have been shown to elicit immune responses. Until now, procedures 
for acquiring biocompatibility measurements of the bioartifical pancreas include 
fabrication and implantation of capsules into the peritoneal cavity of mice, incubation for 
specified periods of time, and retrieval via peritoneal lavage. Labs create quantitative 
scales dependant on the number of cells or cell layers adhered to the capsule walls to 
score the biocompatibility [1, 8-14]. There are several disadvantages to these methods. A 
time line of immune response is hard to determine unless many animals are used because 
 21
only one data point can be obtained per animal. Using many mice allows for more error 
associated with animal variability.  
To circumvent these problems, we propose an alternate method of monitoring 
immune response. In vivo bioluminescence imaging allows measurements of immune 
response to be acquired real time. Transgenic mice expressing the proximal 5’ human 
immunodeficiency virus long terminal repeat, a known Nuclear Factor-kappa Beta (NF-
kB) dependent promoter sequence, are used. NF-kB is a transcription factor that plays a 
critical upstream role in coordinating the inflammatory and wound healing cascade. It 
initiates the transcription of many cytokines, chemokines, adhesion molecules, and 
proinflammatory genes [15-18]. When NF-kB binds to its promoter sequence to initiate 
transcription of immune response proteins, luciferase complementary DNA is also 
produced in the cell. Luciferase, in conjunction with its substrate, luciferin, catalyzes a 
bioluminescent reaction detectable by a sensitive charge coupled device camera. The 
amount of light (photons/sec) detected by the camera is therefore indicative of NF-kB 
activity, which is highly involved in regulating the immune response. These techniques 
allow unlimited measurements of biocompatibility to be made real time. Acquiring 
information from the same mouse repeatedly to construct a time line of immune response 
allows each new data point an accurate reference to the last, instead of relying on data 
points acquired from different animals. This is in part made possible because each mouse 
can be used as its own control. The requirement for fewer animals reduces the reliance on 
statistical analysis and increases the importance of real time data. Collected data can 
reveal important information about the immune response time course. 
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Materials and Methods 
Capsule Fabrication 
 Capsules are fabricated using an air-stripping apparatus. Isolated Islets of 
Langerhans are mixed with the alginate polyanion solution. When the anion drops react 
with the cation solution to form the capsule walls, the islets remain sequestered inside. 
Alginate polyanion drops are sheared with air from the nozzle tip that funnels it. The 
diameters of the droplets are largely regulated by the controlled airflow around the nozzle 
tip. The nozzle tip diameter is also important in determining the polyanion drop size.   
 In order to form the capsule walls, the anion drops are washed in a polycation 
bath of CaCl2. The alginate polyanion is comprised of guluronic and mannuronic acid 
residues which forms a hydrogel when cross linked with divalent cations, for example 
calcium [48]. The reaction time dictates wall thickness. In order to ensure consistent 
reaction times for all anion drops, a novel reactor is used. This reactor is a loop through 
which the CaCl2 solution continuously flows. Once the capsule exits the reactor, it settles 
into a buffer solution, ending the gelling reaction (figure 4).  
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 Figure 4. Schematic of polyanion drop generator and cation solution reactor [49]. 
 
The flow rate and reactor length, which determine reaction time, remain constant. This 
allows equal reaction times for each capsule.  
 Once wall construction is complete, the capsules are washed in poly(methylene-
co-guanidine)hydrochloride (PMCG) to create the capsule semi-permeable membrane. 
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This step is critical for determining pore size and therefore what particle sizes are allowed 
to diffuse through the capsule wall. Next the capsules are coated in another polyanion 
solution followed by one more CaCl2 wash. This forms a final coating while eliminating 
superfluous positive ions from the PMCG solution. 
 These reactions produce capsules, which in this experiment are a transplant group. 
Another transplantation group is the non-coated capsule group. These non-coated 
capsules are the same size as the original capsules, but lack the final polyanion/CaCl2 
coating. They are used as a positive control because exposed positive ions are not 
biocompatible. The PMCG has been shown to induce TNF-α production and necrosis of 
monocytes [8]. To validate the efficacy of the imaging systems ability to discern between 
varying amounts immune response, a positive control is necessary.  
The final transplantation group is the bead group. Beads are made by replacing 
the capsules into the drop generator with alginate. Larger capsules are formed when drops 
are sheared into the polycation reactor, forming larger beads that sequester an average of 
2.5 capsules within. The capsules and beads have the same wall composition, and the 
difference is their diameters. The non-coated and normal capsule have an average 
diameter of .8mm. The beads have an average diameter of 1.4mm.  
 Bead dimensions allow more distance between the mouse and the encapsulated 
islets and leached debris. The beads also distance the only potentially toxic substance 
used in capsule fabrication, PMCG, from the mouse biological medium. The bead group 
was chosen to explore the potential negative effects of increased capsule diameter on NF-
kB activity amidst the theoretical benefits of distancing the foreign cells and potentially 
toxic substances from the mouse biological medium. 
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Surgical Transplantation 
The dorsal-cervical fat is chosen as the site of implantation for several reasons. 
Transplantation into the peritoneum does not allow for even distribution. Free-floating 
capsules are much less likely to show capsular overgrowth, and are easier to recover than 
those embedded in the peritoneal lining. Implantation into the fat pad reduces that 
selection bias. When capsules are transplanted into epididymal fat pads, capsules stay 
localized. Experiments have shown that pericapsular reactions are uniform throughout the 
pad [10, 50]. In addition, initial bioluminescent studies for this experiment show low 
basal NF-kB activity in the dorsal-cervical region relative to other fat pad locations closer 
to organs with elevated basal NF-kB activity. 
The mice are first anesthetized with a 5mg/ml solution of nembutal. Each mouse 
is injected with 1/100 the mouse weight in milliliters. For example, a 30g mouse is 
injected with a .3mL dose of the 5mg/ml nembutol/saline solution. Prior to intra-
peritoneal injection, the mice are anesthetized with gaseous isofluorane to render them 
motionless during IP injection. The injection of nembutal will anesthetize the mice for 
approximately 30-35 minutes.  
 Once anesthetized, each mouse is shaved along the dorsal-cervical fat pad, 
starting just below the base of the skull approximately 1/3 the length of the back. Then 
the mouse limbs are restrained to the surgical table. Once restrained, the shaved skin is 
swabbed with alcohol and the entire mouse is covered in swabbed plastic Saran wrap to 
help prevent infection. 
 Using tweezers and surgical scissors, an incision is made, first in the Saran wrap, 
and then the skin. Care is used to ensure the cut is made superficially into the skin to 
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prevent piercing of the membranous tissue beneath. Once the epidermis is incised, 
another incision is made in the thin membrane that separates the skin from the fat pad that 
lies beneath. Once this membrane is cut, the fat pad is exposed. The fat pad consists of 
sheaths of fat, between which space can be formed. Using surgical tweezer tips, the fat is 
probed until a separation in the sheaths of fat is located. Using the same tweezers, the 
sheaths are separated and held apart, and kept moist with sterile saline as necessary. This 
forms a small pocket into which capsules can be transplanted.  
 Capsules are most easily transported in solution. To provide adequate 
nourishment for the islets, the capsules are stored in a fetal bovine serum solution. Prior 
to transplantation, the capsules are transferred to a sterile saline solution and split into 
aliquots. Aliquots of different capsule types are normalized to surface area. During 
transplantation, the aliquots are siphoned into a pipette tip, and time (several minutes) is 
given to allow the capsules to gather at the bottom of the pipette tip. The pocket into 
which the capsules will be transplanted does not allow a volume of more than a drop or 
two of solution depending on mouse size. To avoid overflow, all capsules must be 
transferred in one to two drops of saline solution only. 
 Once the capsules are transferred, a single suture is tied joining the incised 
membrane that separates the skin and fatty tissue of the dorsal-cervical fat pad. Several 
sutures (as required) are then tied joining the incised epidermis. Each mouse is wrapped 
in gauze for warmth while the effects of the nembutol dissipate. 
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Image Acquisition 
 Each mouse is briefly anesthetized with gaseous isofluorane to render the mice 
immobile for several seconds for intra-peritoneal injection of a 5mg/ml solution of 
nembutal. Each is injected with 1/100 of their respective body weight, in milliliters. For 
example, a 30g mouse is injected with .3mL of the 5mg/ml nembutal in saline solution. 
Once anesthetized, mice are shaved over the dorsal-cervical fat pad from which photon 
counts will be acquired. Then each mouse in injected with a 15mg/ml solution of D-
luciferin potassium salt in H2O (Biosynth International Inc., Naperville, IL). Dosage is 
dependent on weight as is the nembutol, and the injection in intra-peritoneal.  
 After luciferin injection, each mouse is placed stomach down on a pad 
constructed specifically of dark material for imaging. Mice are immobilized on the pad 
by strapping their limbs to the surface. Each mouse head is immobilized by placing pins 
on either side of the head and in front of each ear. This restrains the head from shifting 
during involuntary reflex arcs and muscle spasms while anesthetized. Mouse movement 
must be kept to a minimum because exposure time is three minutes. Maximum 
bioluminescence from the bioluminescent reaction will occur at different times for each 
mouse. In addition, it will occur at different times for the same mouse on different days 
depending on several factors such as metabolism and subtle differences in injection 
location. Therefore, images acquired using 3-minute exposure times are taken 
consecutively for approximately 30 minutes.  
Images are acquired using a XENOGEN IVIS 100 Imaging System and a charge 
coupled device camera (Spectral Instruments Inc.). Once images are acquired, the 
accompanying software (Living Image 2.2)  is used to define a region on the image from 
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which photons are counted. The same area circle, large enough to encompass the dorsal-
cervical region, was used for every image of every mouse. Because consecutive 3-minute 
exposures are taken over 30 minutes, there are approximately 10 resulting images per 
mouse per day. Each image was taken using a high resolution binning of 4, field of view 
25, and all images were automatically background subtracted, flat-fielded, and cosmic. 
The image that renders the highest photon count per mouse is used for that day’s data 
point. These intermediary steps are essential because they offer a standard method by 
which maximum bioluminescence can be obtained under variable conditions. 
 
Luciferase Assay 
 A luciferase assay is performed to correlate photons detected by the camera to in 
vivo histology of the mouse dorsal-cervical fat pad. Small adipose tissue samples, 
approximately .006g, are selected from three mice, one transplanted with capsules, 
another transplanted with capsules lacking a final coating, and a last transplanted with the 
larger beads (a larger capsule, approximately 1.4mm in diameter, sequestering 2-4 
capsules of standard diameter, approximately .8mm in diameter). Samples were taken 
approximately 7 weeks post-transplantation.   
 Each tissue sample is placed in a solution of 1x PBS solution for rinsing. Each 
sample is gently blotted dry and weighed. A diluted Reporter Lysis Buffer (Promega 
Corp., Madison, WI) is added to each sample. Cells containing the luciferase must be 
lysed. For every 1ug tissue, 1uL lysis buffer is added. For each sample, only small 
amounts of buffer are added at first. Fatty tissue is difficult for the buffer to break down 
and requires manual methods of digestion. In this case, a small aliquot of lysis buffer is 
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added to each sample in an epindorph tube, and the tissue then cut with small surgical 
scissors into smaller pieces that enables the buffer to digest more completely and quickly. 
Adding all the buffer at once would hamper this process because there would be too 
much solution in the tube to effectively cut the tissue. The remaining buffer is added to 
each sample after cutting and incubation so the ratio of tissue to buffer is consistent for 
each sample. Results are normalized per gram tissue weight.  
 Each sample is incubated in the buffer for approximately one half hour. At this 
point, the tissue is soft and easily broken, but not completely broken down. Each sample 
is then placed in a thick test tube used for grinding. Each sample is ground with a pestle 
instrument manufactured to fit the diameter of the epindorph tube until the tissue is 
“dissolved” in the lysis buffer. A small aliquot of the resulting solution is taken from each 
sample and placed in epindorph tubes. They are shaken vigorously and then spun for 4 
minutes. The spinning separates the tissue proteins from the luciferase protein. From each 
spun sample, a small consistent aliquot of 20uL is acquired and added to 50uL lysate 
solution (Promega Corp., Madison, WI), which is placed in a Luminometer for luciferase 
protein detection.  
 The lysis buffer, with the dissolved tissue, added to the lysate solution is placed in 
a special tube deigned for use with the Monolight 3010 Luminometer. The luciferase 
catalyzes the bioluminescent reaction with the lysate and the resulting light emittance is 
amplified and detected by a high sensitivity, low noise photomultiplier. The number of 
photons emitted during the reaction is indirectly related to the luciferase content in that 
tissue sample. The resulting units are RLUs, or relative light units.  
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H and E Stain 
An H and E stain was performed to visualize fibrosis surrounding different types 
of capsules. Three tissue samples are extracted, approximately 7 weeks post-
transplantation, from the same three mice used for the luciferase assay, one transplanted 
with capsules, another transplanted with capsules lacking a final coating, and a last 
transplanted with the larger beads.  
 Care is taken to ensure that capsules are embedded in the extracted samples. Each 
sample is suspended in a formulin fixative, provided by the Pathology Core, Vanderbilt 
University.  
 Once suspended in the formulin fixative, the samples are given to the Pathology 
Core, Vanderbilt University for embedding in paraffin blocks. Slices from each block are 
cut to make slides, and those slides containing cross-sections of the polymer-based 
capsules are treated with an H and E stain to mark immune response proteins surrounding 
the capsule.  
 
Trouble Shooting 
 It is important to ensure that the variance in the results is due to inherent bio-
variance and not due to inconsistencies in the experimental procedure. Various 
troubleshooting projects were conducted to exclude any additional error that may be 
contributed by the camera, mouse physiology other than NF-kB activation, tissue 
specificity of the NF-kB transcription factor, effects of repeated shaving (not including 
surgery), and substrate concentration consistency. 
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Camera Consistency 
 In order to exclude any variance in photon count acquisition by the CCD camera, 
small glass beads (mb-Microtec, Switzerland) of constant luminescence are used for 
calibration. Each glass droplet, dimensions .65 x 2.5mm, luminesce at constant intensity 
at 550 +/- 10nm.   
Twenty beads are imaged several times daily over a period of five days to 
determine both long and short term photon count regularity. The average and standard 
deviation are calculated from the images for each bead. The percent standard deviation of 
the average is calculated for each bead (st. dev. / average), and the twenty separate 
percents are averaged to obtain a final average of 4.4%.  
It is unknown whether this 4.4% reflects the camera’s ability to measure a 
constant light source consistently, or whether it reflects the glass bead’s ability to 
luminesce at constant intensity. Regardless, 4.4% is much smaller a ratio than the 
standard deviation to average ratio of 38.5% for the baseline measurements for each 
mouse, an almost 9-fold difference. 
 
Tissue Specificity of the NF-kB Transcription Factor 
The NF-kB transcription factor is tissue specific. It behaves differently depending 
on the tissue. For example, basal NF-kB activity is higher in some tissues than in others. 
In order to determine if there is a marked increase of basal NF-kB variability at the site of 
transplantation compared to elsewhere in the mouse model, a comparison was made 
against the nose. The nose was chosen for its accessibility in the images, and its high 
basal level of NF-kB activation, in contrast to the fat pad. Other parts of the mouse 
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anatomy available are the ears, which are too close to the dorsal-cervical area, the paws, 
which are often covered due to the mouse limb restraints, and the tail, which is often not 
in the image frame, and twitches under anesthesia. The nose is the easiest to isolate.  
 Data from six mice imaged five times over two weeks is used. The images are 
procured and integrated intensities calculated in the same manner described in the 
Materials and Methods section outlining Image Acquisition. For both anatomical regions, 
both the average and the standard deviations are calculated for each mouse using the data 
obtained from the five imaging sessions. For each mouse, the ratio of standard deviation 
to the average (st. dev. / average) is calculated to determine what percent of the average 
the standard deviation represents. Six mice results in six percentages. The average and 
standard deviation of those percentages are calculated for each anatomical region.  
The nose data results in an average of 33 +/- 16%, and the fat pad data results in a ratio of 
42 +/- 10%. These are statistically insignificant, and no conclusion can be easily drawn 
about the variability of NF-kB activation in these two different tissue samples.  
A possible explanation for the larger percent error from the fat pad data is the 
difference in size of the region measurements. The region measurements for the nose 
cover a much smaller area of the mouse than those for the fat pad. The slightest 
variations, such as mouse movement, physiological variations in the mice, could be 
augmented when looking at those effects over a larger surface area. It is logical that the 
fat pad presents a higher ratio.  
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Shaving Effects 
Another possible source of NF-kB activation, other than trauma from surgery and 
immune response to transplant materials is shaving of the skin over the dorsal-cervical fat 
pad. Prior to imaging, each mouse is shaved as needed because fur can mask 
bioluminescent signals. A study was conducted using two mice to determine any adverse 
effects.  
Three baseline measurements of the dorsal-cervical region are taken prior to 
shaving. Prior to the fourth imaging session, each mouse is shaved. Subsequent imaging 
of the dorsal-cervical fat pad is preceded with a shave, regardless of its necessity to 
remove hair; mice require trimming approximately once every one to two weeks. For this 
study, it is important to conduct shaving prior to each imaging session because the effects 
of long-term shaving are to be determined.  
Results indicate an average increase in light emmitance of 41% without fur. This 
increase is expected. However, the purpose of this experiment is to compare the fourth 
imaging session shave day data (before any irritation and subsequent NF-kB activation 
from shaving has a chance to occur) to data acquired during the fifth, sixth, and seventh 
imaging sessions (presumably irritation increases bioluminescence if shaving instigates 
irritation). According to the results, no significant increases in luminescence occurs post 
shave day (data not shown).  
 
Luciferin Saturation Studies 
A potential area of bioluminescent variability is substrate concentration. Doses of 
luciferin are injected into the peritoneal cavity of the mice prior to placement in the 
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imaging chamber. There are many factors that can vary the amount of substrate reaching 
immune response cells in the dorsal-cervical fat pad such as biodistribution, cellular 
uptake, and enzyme kinetics. Because of these factors, it is easy for resulting 
bioluminescence to be proportional to the amount of injected substrate instead of 
proportional to the amount of endogenously produced intracellular luciferase enzyme.  
 To effectively exclude potential substrate problems such as inconsistent dilutions, 
freeze/thaw freezers that may slightly thaw the luciferin solution and reduce potency, 
studies to determine saturation thresholds are conducted. Two mice are used for this 
experiment. It is important to use mice that have already undergone surgery because NF-
kB activation will increase over basal levels, and more luciferase complementary DNA 
will be present.  
For this study, two mice are injected with single, double, and triple doses of 
luciferin during the course of one day, with at least 5 hours separation. Luciferin 
concentration is the same as described in the Materials and Methods section outlining 
Image Acquisition. It is important to conduct this study within a period during which it 
can be assumed significant levels of immune response have not changed. For each 
mouse, the standard deviation of the results for all three dosages is less than the standard 
deviation of baseline measurements for each mouse (data not shown). This indicates that 
the substrate concentrations are at or near appropriate levels to overcome any saturation 
obstacles such as enzyme kinetics, biodistribution, and cellular uptake. To compare 
varying levels of bioluminescence, which is assumed to be indicative of immune 
response, it is important to ensure that limiting reagent is not dependent on levels of 
injected luciferin, but rather on levels of endogenous luciferase. 
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Results 
 As previously mentioned in the Materials and Methods section outlining Image 
Acquisition, images were acquired using consecutive three-minute exposures for 
approximately 30 minutes. Maximum bioluminescence occurs at different times for each 
mouse, and at different times for the same mouse on different days depending on 
metabolism, subtle differences in injection location, cellular uptake, and enzyme kinetics 
(figure 5). 
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Figure 5. Graph of bioluminescent reaction time course after luciferin injection for one 
mouse. 
 
 
 
This inherent variability changes the characteristics of the above graph in figure 4. The 
maximum data point per mouse (16-19 minutes for this mouse on this imaging day) is 
used because it is the most indicative of the total amount of luciferase complimentary 
DNA present at the site of implantation. The maximum point is theoretically consistent 
over multiple image acquisition sessions. Care was taken to ensure that the limiting 
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reagent in this bioluminescent reaction was the luciferase complementary DNA and not 
the injected luciferin, as described in the Trouble Shooting section outlining Luciferin 
Saturation Studies.  
To determine statistically significant differences between transplant groups per 
imaging session, and to compare total bioluminescent activity between transplant groups 
over a period of six weeks, normalization procedures were required. Between three and 
five baseline measurements of the dorsal-cervical fat pad were obtained before surgical 
procedures for each mouse. These measurements were averaged and represent basal NF-
kB activity for each fat pad. This average was used as a base for which every subsequent 
post-surgical measurement could be inferred as a percent increase over basal NF-kB 
activity. This process standardizes varying degrees of basal NF-kB activity across the 
mice.  
Four rounds of surgeries were conducted during the course of the experiment. To 
compare total bioluminescent activity between transplant groups over all six weeks, it 
was important to normalize the time-axis as two of the four transplantations were 
monitored for approximately four weeks. This required multiplying those transplantations 
by a conversion factor obtained from the capsule group from the first transplantation, 
which was monitored over the entire six weeks. An assumption must be made that the 
transplant groups in the two transplantations monitored for only 4 weeks would behave 
similarly to the capsule group in the first. 
Time axis normalization and normalization of transplant group data was 
calculated with respect to the capsule group in each of their respective rounds of surgery 
for several reasons. First, mice were transplanted with capsules in all four rounds of 
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surgery. Second, as described in the Materials and Methods section outlining capsule 
fabrication, fabrication techniques allow for very high reproducibility. The air-stripping 
apparatus allows a high degree of polyanion drop uniformity. The chemical reactor that 
generates the continuous flow of CaCl2 solution allows reaction times to be controlled 
within a few percentage points, which is important because reaction times between the 
alginate drop and the CaCl2 solution dictate membrane thickness. In addition, collection 
of polyanion drops in a beaker of polycation solution allows for sedimentation and 
varying reaction times between the first anion drop to fall compared to the last. Both of 
these phenomenons can result in heterogeneity of wall thickness. The chemical reactor 
ensures uniform capsule exposure to the cation solution. These procedures aid in 
producing capsules under identical conditions [49, 51]. It is for these reasons that every 
transplant group was normalized to the capsule group in that round of surgery. For 
example, the bead group from the second transplantation was normalized to the capsule 
group from the second transplantation; hence, the normalized area under the curve for the 
capsule group is 1 for each surgery. Normalized results from each transplantation were 
then averaged (figure 6). 
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Normalized Area Under the Curve for each Transplant Group Over 6 
Weeks
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Figure 6. Bar graph of normalized area under the curve for each transplant group. All 
transplant groups are normalized to the capsule group, which equals 1. The numbers in 
parenthesis are diameters (mm). Error bars represent standard error of the mean. There is 
no error for the capsule group because the area under the curve is normalized to 1 in all 
transplantations. There is no error for the sham group because they are monitored in only 
one round of transplantation. 
 
 
 
 It can be inferred from the figure 5 that there is little difference in NF-kB activity over a 
six-week period between the capsule, no coat, and sham groups. Activity for the no coat 
and sham group was suppressed approximately 5% below capsule NF-kB activity. 
However, NF-kB activity resulting from bead transplantation was elevated approximately 
31% over capsule activity, statistically significant relative to the capsule transplant group. 
As expected, control group activity was largely suppressed, approximately 83% below 
capsule activity. 
 The normalized time line of NF-kB activity for each transplant group is presented 
in the following graphs (figure 7-11).  
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Transplanted Capsule Normalized NF-kB Activity Over Time
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Figure 7. Graph of normalized NF-kB activity for mice transplanted with capsules. Day 0 
is surgery day, and is represented by the average of all pre-operative baseline 
measurements for all mice in the group. Error bars represent Standard Error of the Mean. 
N = 11. 
 
 
 
Transplanted Bead Normalized NF-kB Activity Over Time
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Figure 8. Graph of normalized NF-kB activity for mice transplanted with beads. Day 0 is 
surgery day, and is represented by the average of all pre-operative baseline measurements 
for all mice in the group. Error bars represent Standard Error of the Mean. N = 11. 
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Transplanted Non-Coated Capsule Normalized NF-kB Activity Over Time
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Figure 9. Graph of normalized NF-kB activity for mice transplanted with non-coated 
capsules. Day 0 is surgery day, and is represented by the average of all pre-operative 
baseline measurements for all mice in the group. Error bars represent Standard Error of 
the Mean. N = 8. 
 
 
 
Sham Group Normalized NF-kB Activity Over Time
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Figure 10. Graph of normalized NF-kB activity for sham surgery mice. Day 0 is surgery 
day, and is represented by the average of all pre-operative baseline measurements for all 
mice in the group. Error bars represent Standard Error of the Mean. N = 3. 
 
 
 
 
 41
Control Group Normalized NF-kB Activity Over Time
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Figure 11. Graph of NF-kB activity for control mice. Day 0 is surgery day for the mice in 
other groups, and is represented by the average of all baseline measurements for the mice 
in the control group. Error bard represent Standard Error of the Mean. N = 3. 
 
 
 
Statistical analyses reveal no statistically significant differences between groups per 
imaging session. The only point at which there is a statistically significant difference 
between the medians of transplant groups is between the bead and sham groups, 8 days 
post surgery. The following table shows Mann-Whitney P values for comparisons 
calculated between each group (Table 1). 
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Table 1. Table of Mann-Whitney P values for comparisons between groups. P<.05 is 
statistically significant and marked in bold with asterisks. Cells marked with a Not 
Available indicate that sample numbers are too small to perform the Mann-Whitney Test. 
The Sham vs. Control group is not included because sample numbers are too small for all 
dates. X-axis is days post surgery. 
 8 days 11 days 14 days 17 days 20 days 25 days 28 days 32 days 39 days 
          
Bead vs. Capsule 0.279 0.189 0.393 0.841 0.948 0.948 1 0.721 0.645 
 (16) (22) (22) (10) (22) (22) (22) (16) (16) 
          
Bead vs. No Coat 0.721 0.591 0.967 0.73 0.591 0.901 0.65 0.878 0.798 
 (16) (19) (19) (9) (19) (19) (19) (16) (16) 
          
Bead vs. Sham **0.012** 0.876 0.876 NA 0.119 0.533 0.876 0.63 0.63 
 (11) (14) (14)  (14) (14) (14) (11) (11) 
          
Bead vs. Control 0.279 0.276 0.35 NA 0.276 0.213 0.64 0.497 0.279 
 (11) (14) (14)  (14) (14) (14) (11) (11) 
          
Capsule vs. No Coat 0.442 0.65 0.71 0.556 0.65 0.773 0.483 1 0.645 
 (16) (19) (19) (9) (19) (19) (19) (16) (16) 
          
Capsule vs. Sham 0.376 0.436 0.64 NA 0.062 0.436 0.35 0.376 0.279 
 (11) (14) (14)  (14) (14) (14) (11) (11) 
          
Capsule vs. Control 0.376 0.533 0.35 NA 0.436 0.35 0.436 0.279 0.133 
 (11) (14) (14)  (14) (14) (14) (11) (11) 
          
No Coat vs. Sham 0.376 0.921 1 NA 0.776 0.376 1 0.776 0.776 
 (11) (11) (11)  (11) (11) (11) (11) (11) 
          
No Coat vs. Control 0.194 0.279 0.279 NA 0.376 0.376 0.376 0.497 0.497 
 (11) (11) (11)  (11) (11) (11) (11) (11) 
 
 
 
To ensure that data obtained from imaging is indicative of varying quantities of 
luciferase complementary DNA, a luciferase assay was performed on three mice, one 
transplanted with beads, another with capsules, and the last with non-coated capsules. 
The following diagram displays the raw integrated intensities for each mouse at the time 
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of assay and the corresponding value of relative light units projected by the spectrometer 
(figure 12-13).  
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Figure 12. Graph of integrated intensities from four mice the day before luciferase assay. 
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Figure 13. Results of luciferase assay from mice transplanted with capsules, beads, and 
uncoated capsules. Data is normalized per gram tissue weight.  
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The no coat mouse exhibited approximately a quarter to a sixth the integrated intensity of 
the capsule and bead mice, respectively. Accordingly, the luciferase assay data obtained 
shows the no coat mouse tissue sample contained approximately half to three fifths the 
luciferase quantity per gram tissue of the capsule and bead mice, respectively. All three 
transplant groups showed significantly greater amounts of luciferase than the wild type 
mouse.  
 In addition to the luciferase assay, retrieved capsules still embedded in the dorsal-
cervical fat pad from the same three mice were extricated and embedded for H and E 
staining. Photographs of each cross section show a markedly higher congregation of 
immune response proteins surrounding the bead and capsule walls than the no coat walls 
(figure 14-16).  
 
 
Figure 14. Image of H and E stained cross section of excised bead from dorsal-cervical 
fat pad. Aqua cells are adipose tissue. Purple grain surrounding bead wall is fibrosis. 
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Figure 15. Image of H and E stained cross section of excised capsule from dorsal-
cervical fat pad. Purple grain surrounding capsule wall is fibrosis.  
 
 
 
 
Figure 16. Image of Hand E stained cross section of excised non-coated capsule from the 
no coat transplant group dorsal-cervical fat pad. Purple grain surrounding capsule wall is 
fibrosis, of which there is considerably less compared to excised beads and capsules with 
final coating. 
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It is important to note that these three mice are not necessarily representative of their 
perspective transplant group, but rather they verify the correlation between 
bioluminescent intensities acquired from the camera and mouse histology. 
 
Discussion 
Results from this experiment indicate that this imaging modality can be a 
proficient methodology for monitoring immune response real time and in vivo using the 
NF-kB transcription factor as a bioluminescent marker. It is capable of determining 
statistically significant differences between pre and postoperative data points per mouse, 
as well as differences in NF-kB activity between transplant groups over a six-week 
period of time.  
Five transplant groups were monitored over four rounds of surgeries, a capsule, 
no coat, bead, sham, and control group. The capsule group is those mice implanted with 
standard uniform capsules approximately .8mm in diameter. The non-coated capsules are 
capsules of the same size, but lacking a final biological coating to be used as a positive 
control, as described in the Materials and Methods section outlining capsule fabrication. 
The control group consists of mice that did not undergo surgery, monitored for the effects 
of repeated nembutol and luciferin injections, and used as a negative control. The bead 
group is essentially identical to the capsule group in surface composition, but has an 
average diameter of 1.4mm. The sham group consists of mice that experienced surgical 
procedures, but no implant was left in the fat pad, allowing us to monitor surgical effects 
on NF-kB activity. These transplant groups were chosen to allow comparisons between 
both the capsule wall composition and size parameters to be made. 
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The sham transplant group time line of NF-kB activity shows an initial peak 
shortly after surgery, and then a slow decrease in NF-kB activity over several weeks back 
to basal levels. The bead, capsule, and no coat groups show similar responses, indicating 
that they, too, experienced initial increases in NF-kB activity due to surgical procedures. 
Both the no coat and sham groups show only a 5% decrease in NF-kB activity compared 
to the capsule group over six weeks. Because the normalized area under the curve for the 
capsule group is close to the sham surgery group, host immune response to the capsules is 
negligible compared to the trauma of surgery. This is potentially encouraging news for 
the success of encapsulated islets.  
The same conclusion can be drawn about the no coat group. This is particularly 
interesting because even those capsules fabricated for use as a positive control 
demonstrate a degree of immune response still masked by the traumatic effects of 
surgical procedures. Within the variables modified in the production of capsules, the 
biocompatibility parameter has negligible effects on host NF-kB activity compared to 
surgical procedures. 
The bead group shows a 31% increase in NF-kB activity over the capsule group 
and the sham group, indicating that the size parameter effects NF-kB activity in excess of 
the effects of surgical procedures over a six-week period. These results support findings 
by Robitaille et al. who found that larger capsules elicit a greater immune response when 
normalized to surface area, although the capsules studied are smaller in scale than those 
used in this experiment [10]. Experiments conducted by Paul de Vos et al. concluded that 
capsules of an approximate .8mm diameter have a lower percentage of incomplete (islet 
protrudes from microcapsule) and defective (sequesters islet but with localized defects) 
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capsules than capsules of an approximate 1.4mm diameter [52]. However, these results 
are an indirect representation of biocompatibility and more a direct representation of the 
limits of their capsule fabrication techniques, as techniques, chemicals, reactions times, 
and equipment change from one lab to another. Care is taken in this experiment to not 
only normalize transplant materials to a constant surface area, but also to ensure that 
there are no discontinuities in the capsule walls. Several experiments have been 
conducted to determine the effects of capsule size on water activity, mechanical strength, 
transport behavior, porosity, in vitro insulin kinetics, and TNF-α permeability, but not in 
vivo biocompatibility studies directly [53, 54].  
Although the exact mechanisms for the apparent effect of capsule size on 
biocompatibility are not clear, there are several theories. Because both the capsule and 
bead surfaces are similar in composition, and total transplanted surface areas are 
normalized before transplantation, both individual volume differences between the 
capsules and beads, and the total implant volume may have an effect. The transplanted 
beads occupy a larger total volume than the capsules. Larger volumes may provoke 
greater stress on neighboring cells. This may affect the rapidity of or ability to mount 
immune responses. Because capsules and beads are normalized to surface area, 
differences in the total number of implanted capsules (18) and beads (6) may also have an 
effect. Because the site of transplantation is close to the incision, it is more likely that 
larger implant volumes have no more an effect on inflammation than do the capsules, but 
rather a more negative effect on wound healing. The sham surgery indicates that wound 
healing does affect NF-kB activity. 
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This size dependence on capsule biocompatibility is particularly intriguing 
because of the PMCG distribution. It is an element used in capsule fabrication considered 
to elicit an immune response (T.G. Wang and Michael Haralson, private communication). 
Normalizing transplantation materials to surface area results in the transplantation of 18 
capsules per mouse, and 6 beads per mouse. There are an average of 2.5 capsules 
sequestered within each bead. The process of bead formation does not require any 
additional PMCG. Therefore, not only is there less PMCG, on average, in those mice 
transplanted with beads, but they are also positioned further from the biological medium 
in the mouse. In addition to the PMCG, the mouse is also positioned further from the 
islets and its biological debris. These characteristics would lead one to hypothesize that 
the beads could be more biocompatible than the capsules, however, the effect of volume 
must be masking those effects, if any.  
In conclusion, this imaging modality can be a practical methodology for 
monitoring immune response using the NF-kB transcription factor as a bioluminescent 
marker. Until now, biocompatibility measurements of the bioartifical pancreas have been 
made histologically, which allows only one data point to be acquired per mouse. 
Acquiring information from the same mouse repeatedly to construct a time line of 
immune response allows each new data point an accurate reference to the last, instead of 
relying on data points acquired from different animals. This is in part made possible 
because each mouse can be used as its own control. The requirement for fewer animals 
reduces the importance for statistical analysis and increases the importance for real time 
data. These advantages allow the following conclusions to be made about the efficacy of 
this imaging modality. It is sensitive enough to significantly differentiate between pre and 
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post operative data points per mouse, but not sensitive enough to discern differences 
between transplant groups per imaging session. However, it is capable of determining 
differences between transplant groups over extended periods of time. We found that the 
surgery itself and the size of transplant have more of an effect on capsule 
biocompatibility than does the wall composition parameter in this experiment. Neither the 
capsule nor the no coat groups are able to provoke a host immune response greater than 
that elicited by surgical procedures. Only beads with a greater diameter than the capsule 
and no coat groups are able to elicit host immune responses in excess of those triggered 
by surgical procedures. 
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CHAPTER III 
 
FUTURE WORK 
 
This imaging system, in conjunction with an NF-kB bioluminescent marker, is an 
effective means by which differences in biocompatibility due to capsule size can be 
scored over a period of time. However, the traumatic effects of surgery are an 
impediment to determining those differences, and even mask the effects of varying wall 
compositions on biocompatibility. Perhaps if the effects of surgical procedures could be 
minimized it would provide starker bioluminescent differences between capsules of 
varying sizes, present differences in NF-kB activity between capsules with varying wall 
compositions, and perhaps allow statistically significant differences per imaging session 
to surface.  
Alternative surgical techniques that do not cause as much trauma may be useful. 
For example, a syringe with a small enough gauge needle to allow passage of the 
capsules could be used. Then, incisions would not be necessary, and the skin could be 
punctured far from the dorsal-cervical fat pad from which photon counts are acquired. 
This technique would deposit the capsules between the skin and the fat pad. Not having 
an incision in the skin would have to keep the capsules immobilized between the skin and 
the fat, since it would be difficult to make the fatty pockets into which the capsules were 
transplanted.  
One potential problem with current techniques, as previously mentioned, is the 
overflow of capsules from the fatty pocket, from which one or two capsules could be 
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spilled during surgery. The proposed method may eliminate that variability. In addition, 
using the proposed technique would greatly reduce the chances of infection, and if 
infection did occur, it would not be at the area of photon count acquisition.   
This imaging modality shows size dependant results. It would be interesting to 
explore those effects more thoroughly. Fabricated capsules of sequential sizes could be 
used and monitored for their effects on NF-kB activation. As mentioned in the discussion 
section, previous experiments have been conducted using capsules of sequential sizes, 
however, the results indirectly provide biocompatibility differences as a function of 
capsule integrity, not scored fibrosis.  
Additionally, to assess the hypothesis that implant volumes may have an effect on 
NF-kB activity, it may be interesting to normalize the implants to volume instead of 
surface area. This would allow two parameters to be tested, capsules of homogenous 
volume and differing total implant volumes, but also capsules of heterogeneous volumes 
and a constant total implant volume, to determine the effects of varying numbers of 
implanted capsules on NF-kB activity.  
It is also important to note that this imaging system may in fact be sensitive 
enough to determine differences between NF-kB activity elicited by all transplant groups 
if more than 3 minutes worth of data could be collected every 48 to 72 hours. Those three 
minutes represent .1% to .07% of the total time elapsed in 48 to 72 hours. If more data 
could be collected over those hours and then integrated, it may result in statistically 
significant differences between the transplant groups because a more accurate time 
course of NF-kB activity would be revealed. More data could allow trends in NF-kB 
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activity to surface that were somewhat obscured by the inherent noise associated with 
using live animals in this experiment, for example trauma due to surgery. 
 Another possible improvement that could be made to this experiment is to change 
the bioluminescent marker. Perhaps no matter how often measurements of NF-kB activity 
are made, the NF-kB transcription factor is important to too many cell signaling pathways 
involved in the inflammatory and wound healing cascades to determine statistically 
significant data. It may be beneficial to use this bioluminescent technology to mark the 
activity of other transcription factors, or perhaps others in conjunction with NF-kB. This 
may result in a needed reduction of background noise.  
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